Exemestane: A milestone against breast cancer

Journal of Postgraduate Medicine

Volumn 53, Issue 2, 2007, Pages 135-138

  Shetty, Y ^a   Chakkarwar, P ^a   Acharya, S ^a   Rajadhyaksha, V ^b  

^a KEM HOSPITAL   (India)

^b PFIZER INC   (United States)

Author keywords

Aromatase inhibitors; Breast cancer; Hormonal therapy

Indexed keywords

AMINOGLUTETHIMIDE; ANASTROZOLE; AROMATASE INHIBITOR; EXEMESTANE; LETROZOLE; MEGESTROL ACETATE; TAMOXIFEN;

ACNE; ADJUVANT THERAPY; ALOPECIA; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER RELAPSE; CANCER SURVIVAL; CANCER THERAPY; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; DIZZINESS; DRUG ABSORPTION; DRUG BINDING; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG MECHANISM; DRUG METABOLISM; DRUG SAFETY; DRUG TOLERABILITY; ENZYME INHIBITION; FATIGUE; HOT FLUSH; HUMAN; HYPERTRICHOSIS; NAUSEA; NONHUMAN; RECOMMENDED DRUG DOSE; REVIEW; SIDE EFFECT; SWEATING; THROMBOEMBOLISM; TRIACYLGLYCEROL BLOOD LEVEL; WEIGHT GAIN;

EID: 34249289381     PISSN: 00223859     EISSN: None     Source Type: Journal    
DOI: 10.4103/0022-3859.32218     Document Type: Review

References (28)

1. Pan American health organization [online]. Available from: http://www.paho.org/english/ad/dpc/nc/pcc-breast-cancerguidelines. htm. [Last assessed on 2006 Dec 13].
2. Lonning PE. Aromatase inhibitors and inactivators in breast cancer. BMJ 2001;323:880-1.
3. Clemett D, Lamb HM. Exemestane a review of its use in postmenopausal women with advanced breast cancer. Drugs 2000;59:1279-96.
4. Mauras N, Lima J, Patel D, Rini A, di Salle E, Kwok A, et al. Pharmacokinetics and dose finding of a potent aromatase inhibitor, aromasin (exemestane), in young males. J Clin Endocrinol Metab 2003;88:5951-6.
5. Campos SM. Aromatase inhibitors for breast cancer in post menopausal women. Oncologist 2004;9:126-36.
6. Dowsett M. Drug and hormone interactions of aromatase inhibitors. Endocr Relat Cancer 1999;6:181-5.
7. Miller WR. Biology of aromatase inhibitors: Pharmacology/endocrinology within the breast. Endocr Relat Cancer 1999;6:187-95.
8. Tahara M, Nomura S, Hashimoto M. Pharmacological and clinical profile of exemestane (Aromasin), a novel irreversible aromatase inhibitor. Nippon Yakurigaku Zasshi 2003;122:345-54.
9. Miller WR, Dixon JM. Endocrine and clinical endpoints of exemestane as neoadjuvant therapy. Cancer Control 2002;9:9-15.
10. Goss P. Anti-aromatase agents in the treatment and prevention of breast cancer. Cancer Control 2002;9:2-8.
11. Dank M. The role of aromasin in the hormonal therapy of breast cancer. POR 2002;8:87-92.
12. Lake DE, Hudis C. Aromatase inhibitors in breast cancer: An update. Cancer Control 2002;9:490-8.
13. Ligibel JA, Winer EP. Clinical differences among the aromatase inhibitors. Clin Cancer Res 2003;9:473S-9S.
14. Joensuu H, Ejlertsen B, Lonning PE, Rutqvist LE. Aromatase inhibitors in the treatment of early and advanced breast cancer. Acta Oncologica 2005;44:23-31.
15. Coombes RC, Kilburn LS, Snowdon CF, Paridaens R, Coleman RE, Jones SE, et al. Survival and safety of exemestane versus tamoxifen after 2-3 years' tamoxifen treatment (Intergroup Exemestane Study): A randomized controlled trial. Lancet 2007;369:559-70.
16. Coombes RC, Hall E, Gibson LJ, Paridaens R, Jassem J, Delozier T, et al. A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer. N Engl J Med 2004;350:1081-92.
17. Goss P. Anti-aromatase agents in the treatment and prevention of breast cancer. Cancer Control 2002;9:2-8.
18. Pritchard KI. Endocrine therapy of advanced disease: Analysis and implications of the existing data. Clin Cancer Res 2003;9:460S-7S.
19. Goss PE, Strasser-Weippl K. Prevention strategies with aromatase inhibitors. Clin Cancer Res 2004;10:372S-9S.
20. Buzdar AU. Pharmacology and pharmacokinetics of the newer generation aromatase inhibitors. Clin Cancer Res 2003;9:468S-72S.
21. Physicians' Education Resource [Online]. Available from: http://cancerpublications.com/newsletter/breast/caas/v7n7/article3/article.html. [Last assessed on 2007 Feb 18].
22. Lonning PE, Geisler J, Krag LE, Erikstein B, Bremnes Y, Hagen AI, et al. Effects of exemestane administered for 2 years versus placebo on bone mineral density, bone biomarkers and plasma lipids in patients with surgically resected early breast cancer. J Clin Oncol 2005;23:5126-37.
23. Markopoulos C, Polychronis A, Zobolas V, Xepapadakis G, Papadiamantis J, Koukouras D, et al. The effect of exemestane on the lipidemic profile of postmenopausal early breast cancer patients: Preliminary results of the TEAM Greek sub-study. Breast Cancer Res Treat 2005;93:61-6.
24. Anker GB, Refsum H, Ueland PM, Johannessen DC, Lien EA, Lonning PE. Influence of aromatase inhibitors on plasma total homocysteine in postmenopausal breast cancer patients. Clin Chem 1999;45:252-6.
25. Paridaens R, Dirix L, Lohrisch C, Beex L, Nooij M, Cameron D, et al. Mature results of a randomized phase II multicenter study of exemestane versus tamoxifen as first-line hormone therapy for postmenopausal women with metastatic breast cancer. Ann Oncol 2003;14:1391-8.
26. Jannuzzo MG, Poggesi I, Spinelli R, Rocchetti M, Cicioni P, Buchan P. The effects of degree of hepatic or renal impairment on the pharmacokinetics of exemestane in postmenopausal women. Cancer Chemother Pharmacol 2004;53:475-81.
27. Beltrame D, di Salle E, Giavini E, Gunnarsson K, Brughera M. Reproductive toxicity of exemestane, an antitumoral aromatase inactivator, in rats and rabbits. Reprod Toxicol 2001;15:195-213.
28. Campos SM. Aromatase inhibitors for breast cancer in post menopausal women. Oncologist 2004;9:126-36.